{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06521476",
            "orgStudyIdInfo": {
                "id": "STUDY23100016"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01DA059465",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01DA059465"
                }
            ],
            "organization": {
                "fullName": "University of Pittsburgh",
                "class": "OTHER"
            },
            "briefTitle": "Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder",
            "officialTitle": "Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder",
            "study": "acetazolamide-in-central-sleep-apnea-patients-using-medication-for-opioid-use-disorder"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-07-19",
            "studyFirstSubmitQcDate": "2024-07-19",
            "studyFirstPostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Sanjay R Patel",
                "investigatorTitle": "Professor",
                "investigatorAffiliation": "University of Pittsburgh"
            },
            "leadSponsor": {
                "name": "Sanjay R Patel",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Patients with opioid use disorder treated with either methadone or buprenorphine are at risk of developing central sleep apnea (CSA) from these medications. Investigators will conduct a mechanistic trial using acetazolamide, a medicine known to improve CSA in other settings, to determine if acetazolamide can improve CSA due to medication for opioid use disorder and whether this leads to physiologic changes that might lead to reduced drug craving. Patients treated with medication for opioid use disorder and who have central sleep apnea will be randomized to treatment with acetazolamide or matching placebo for 7 days. At the end of the 7 days, they will undergo an overnight sleep study to assess the impact on breathing during sleep as well as sleep quality. In addition, measures of sympathetic tone, anxiety, arousal, cognition, and drug craving will be measured to determine if treatment of CSA with acetazolamide can produce physiologic changes that might contribue to improved health.",
            "detailedDescription": "Medications used to treat opioid use disorder (MOUD) such as methadone and buprenorphine have been found to cause central sleep apnea (CSA), but the clinical ramifications are unclear. It has been hypothesized that the sleep fragmentation and intermittent hypoxemia caused by CSA from MOUD may lead to sympathetic activation, nocturnal arousal, increased anxiety, and cognitive impairment that may in turn increase drug craving and drug relapse. This mechanistic study will evaluate the potential adverse effect of CSA in patients on MOUD by evaluating the impact of acetazolamide to improve CSA and thereby lead to downstream physiologic changes in measures of sleep quality, sympathetic tone, nocturnal arousal, anxiety, cognitive functioning, and drug craving.\n\nEligible individuals will undergo an overnight research visit including overnight polysomnography, assessments of autonomic tone, sleep quality, nocturnal arousal, emotional distress, cognitive testing, and drug craving. Individuals with opioid-induced CSA will be randomized into a parallel-arm trial of acetazolamide vs. placebo with overnight research visit for outcome assessment at 7 days."
        },
        "conditionsModule": {
            "conditions": [
                "Central Sleep Apnea Comorbid With Opioid Use"
            ],
            "keywords": [
                "Acetazolamide",
                "Opioid Use Disorder",
                "Medication for opioid use disorder (MOUD)",
                "Methadone",
                "Buprenorphine"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Participants will be randomized in 1:1 fashion to one of two parallel arms (active drug versus placebo).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Placebo pill matched to look like active drug.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 40,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Acetazolamide",
                    "type": "EXPERIMENTAL",
                    "description": "All participants in this group will receive one acetazolamide 250 mg pill in the evening for 7 days.",
                    "interventionNames": [
                        "Drug: Acetazolamide"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "All participants in this group will receive one matching placebo pill in the evening for 7 days.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Acetazolamide",
                    "description": "Oral acetazolamide 250 mg daily for 7 days",
                    "armGroupLabels": [
                        "Acetazolamide"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Oral placebo daily for 7 days",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Central Apnea Index (CAI)",
                    "description": "The number of central apneas per hour of sleep, assessed by overnight polysomnography.\n\n* It can range from 0 to undefined events per hour.\n* Higher values indicate more severe central sleep apnea.",
                    "timeFrame": "7 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "NREM LF/HF ratio",
                    "description": "The ratio of low frequency to high frequency spectral power from heart rate variability analysis of ECG collected during NREM sleep on overnight polysomnography.",
                    "timeFrame": "7 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients on Medication for Opioid Use Disorder (MOUD) with central sleep apnea.\n\nExclusion Criteria:\n\n* Sleep-related Hypoventilation.\n* Other causes of Central Sleep Apnea besides Opioid Use.\n* Pregnancy.\n* Contraindications for Acetazolamide.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "100 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Elizabeth Stempkowski",
                    "role": "CONTACT",
                    "phone": "412-648-9507",
                    "email": "stempkowskiem@upmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Sanjay R Patel, MD",
                    "affiliation": "University of Pittsburgh",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Pittsburgh",
                    "city": "Pittsburgh",
                    "state": "Pennsylvania",
                    "zip": "15213",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Elizabeth Stempkowski",
                            "role": "CONTACT",
                            "phone": "412-648-9507",
                            "email": "stempkowskiem@upmc.edu"
                        },
                        {
                            "name": "Sanjay R Patel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Venkatesh Krishnamurthy, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Tae Woo Park, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Kristine Wilckens, PhD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.44062,
                        "lon": -79.99589
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Individual Participant Data (IPD) from this clinical trial will be shared with other researchers. The IPD to be shared includes final closed dataset (after de-identification). All data will be released according to the specific timelines stated in the NIH Policy, ensuring no compromise to privacy, confidentiality, proprietary interests, national security, or law enforcement activities. These data will be submitted to a NIH-funded data registry for data sharing purposes.",
            "infoTypes": [
                "STUDY_PROTOCOL"
            ],
            "timeFrame": "The IPD will become available within 1 year of analysis of primary outcome. This data will be accessible on an NIH-sponsored platform for as long as the agency maintains it.",
            "accessCriteria": "IPD will be available through a NIH funded registry. Access to the IPD will be governed by the policies and procedures of NIH."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001049",
                    "term": "Apnea"
                },
                {
                    "id": "D000012891",
                    "term": "Sleep Apnea Syndromes"
                },
                {
                    "id": "D000020182",
                    "term": "Sleep Apnea, Central"
                },
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012120",
                    "term": "Respiration Disorders"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000012818",
                    "term": "Signs and Symptoms, Respiratory"
                },
                {
                    "id": "D000020919",
                    "term": "Sleep Disorders, Intrinsic"
                },
                {
                    "id": "D000020920",
                    "term": "Dyssomnias"
                },
                {
                    "id": "D000012893",
                    "term": "Sleep Wake Disorders"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4361",
                    "name": "Apnea",
                    "asFound": "Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15694",
                    "name": "Sleep Apnea Syndromes",
                    "asFound": "Sleep Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M22011",
                    "name": "Sleep Apnea, Central",
                    "asFound": "Central Sleep Apnea",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Opioid Use Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14957",
                    "name": "Respiration Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15623",
                    "name": "Signs and Symptoms, Respiratory",
                    "relevance": "LOW"
                },
                {
                    "id": "M22242",
                    "name": "Parasomnias",
                    "relevance": "LOW"
                },
                {
                    "id": "M22654",
                    "name": "Sleep Disorders, Intrinsic",
                    "relevance": "LOW"
                },
                {
                    "id": "M22655",
                    "name": "Dyssomnias",
                    "relevance": "LOW"
                },
                {
                    "id": "M15696",
                    "name": "Sleep Wake Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000086",
                    "term": "Acetazolamide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000927",
                    "term": "Anticonvulsants"
                },
                {
                    "id": "D000002257",
                    "term": "Carbonic Anhydrase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000004232",
                    "term": "Diuretics"
                },
                {
                    "id": "D000045283",
                    "term": "Natriuretic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M11671",
                    "name": "Methadone",
                    "relevance": "LOW"
                },
                {
                    "id": "M2536",
                    "name": "Acetazolamide",
                    "asFound": "One day",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5317",
                    "name": "Buprenorphine",
                    "relevance": "LOW"
                },
                {
                    "id": "M4246",
                    "name": "Anticonvulsants",
                    "relevance": "LOW"
                },
                {
                    "id": "M5515",
                    "name": "Carbonic Anhydrase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7411",
                    "name": "Diuretics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnTuAg",
                    "name": "Antitussive Agents"
                },
                {
                    "abbrev": "Resp",
                    "name": "Respiratory System Agents"
                },
                {
                    "abbrev": "NaAg",
                    "name": "Natriuretic Agents"
                },
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                }
            ]
        }
    },
    "hasResults": false
}